Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for Acute Migraine in Japanese Subjects
NCT05399459Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rimegepant in migraine, sponsored by Pfizer. Started Aug 2022; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05399459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399459.